MAK Capital

MARABio is a biotechnology company focused on the detection and prevention of severe forms of Autism Spectrum Disorder (ASD). The firm specializes in maternal autoantibody-related autism testing, which assesses the risk of ASD by identifying a unique cluster of antibodies in mothers that target proteins in the developing brains of their children. This licensed technology allows for early intervention, enabling mothers to initiate targeted behavioral therapies if their children show signs of developmental delay. By providing critical insights into the maternal health factors associated with autism, MARABio aims to improve outcomes for children at risk for ASD.

Noveome Biotherapeutics, Inc. is a clinical-stage biotherapeutics company based in Pittsburgh, Pennsylvania, founded in 2000. The company develops innovative biotherapeutic products aimed at addressing complex biological processes, particularly in the repair of inflamed or damaged tissues. Its lead product, ST266, is designed to modulate inflammation, enhance wound healing, promote bone restoration, restore nerve function, and facilitate cellular regeneration. Noveome's therapies leverage a range of biologic components at physiological concentrations that work synergistically to deliver anti-inflammatory, neuroprotective, and vascular integrity-preserving effects, providing healthcare providers with advanced treatment options for various complex diseases.

Trailhead Biosystems specializes in the development of cell therapies by integrating hardware and software services. The company focuses on advancing biotechnology and cell therapeutics through a combination of developmental biology and computerized experimental design. This approach allows healthcare clients to optimize process-specific parameters efficiently, reducing the time and number of experiments required to evaluate multiple variables. By streamlining the development of cell therapies, Trailhead Biosystems supports clients in creating innovative therapeutic solutions.